Colorectal cancer (CRC) survival is longer when it’s the first of multiple primary malignancies than when it’s the second or solo, new data suggest. The findings came from a retrospective ...

Patients had a small but nonsignificant survival advantage when continuing with anti-VEGF therapy in the second-line instead of switching to anti-EGFR therapy.

Although training primary care providers in shared decision-making did not significantly improve colorectal cancer concordance or screening rates in older adults, at least 5 minutes of discussion ...